ArticleThe Journal of clinical investigation2002
Human HTm4 is a hematopoietic cell cycle regulator.
Article in The Journal of clinical investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 64 citations in OpenAlex.
- TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Decitabine induces cell differentiation and growth inhibition accompanied by upregulation of microRNA-143 and MS4A3 in the myelodysplastic syndromes-derived leukemic cell line MDS-L.Oncology letters · 2026Article
- Integrative multi-omics analysis identified FUT9 and MS4A3 as novel immune-phenotype and prognosis biomarkers for colorectal cancer and analyze the role of FUT9 in oncoimmunology.Scientific reports · 2026Article
- MS4A superfamily molecules in tumors, Alzheimer's and autoimmune diseases.Frontiers in immunology · 2024Review
- Identification of Potential Crucial Biomarkers in STEMI Through Integrated Bioinformatic Analysis.Arquivos brasileiros de cardiologia · 2024Article
- Enzyme mechanistic studies of NMA1982, a protein tyrosine phosphatase and potential virulence factor in Neisseria meningitidis.Scientific reports · 2023Article
- Vitamin C derivative/AA2P promotes erythroid differentiation by upregulatingLife medicine · 2023Article
- MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia.Cell biology and toxicology · 2023Article
- Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer.International journal of general medicine · 2023Article
- Differential expression and regulation of MS4A family members in myeloid cells in physiological and pathological conditions.Journal of leukocyte biology · 2022Article
- Article
- Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.Oncotarget · 2018Article
- An update on vitamin B12-related gene polymorphisms and B12 status.Genes & nutrition · 2018Review
- MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.Immunology and cell biology · 2017Article
- The MS4A family: counting past 1, 2 and 3.Immunology and cell biology · 2016Review
- A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis.PloS one · 2016Article
- Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells.Oncotarget · 2015Article
- Changes in transcriptome of macrophages in atherosclerosis.Journal of cellular and molecular medicine · 2015Review
- The CD20 homologue MS4A4 directs trafficking of KIT toward clathrin-independent endocytosis pathways and thus regulates receptor signaling and recycling.Molecular biology of the cell · 2015Article
- EVI1 promotes tumor growth via transcriptional repression of MS4A3.Journal of hematology & oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 3 countries.
Funding
Abstract
Proper control of cell cycle progression is critical for the constant self-renewal, differentiation, and homeostasis of the hematopoietic system. Cells of all types share the common cell cycle regulators. The different expression patterns of common regulators, in a broad sense, define cell-type or lineage specificity. However, there remains the possibility of hematopoietic cell cycle regulators tailored to the demands of the hematopoietic system. Here we describe a novel protein, HTm4, which serves as a hematopoietic cell cycle regulator. Our data indicate that HTm4 is expressed in hematopoietic tissues and is tightly regulated during the differentiation of hematopoietic stem cells. It binds to cyclin-dependent kinase-associated (CDK-associated) phosphatase-CDK2 (KAP-CDK2) complexes, and the three proteins demonstrate similar patterns of cellular expression in human lymphoid tissues. HTm4 stimulates the phosphatase activity of KAP, and its C-terminal region is required for binding to KAP-CDK2 complexes and the modulation of KAP activity. Overexpression of HTm4 can cause cell cycle arrest at the G(0)/G(1) phase. Thus, HTm4 is a novel hematopoietic modulator for the G(1)-S cell cycle transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.